title: Diverging trends in incidence and mortality, and improved survival of non-Hodgkin's lymphoma, in the Netherlands, 1989-2007.
abstract: BACKGROUND
  We studied progress in the fight against non-Hodgkin's lymphoma (NHL) in the Netherlands by describing the changes in incidence, treatment, relative survival, and mortality during 1989-2007.
  
  
  METHODS
  We included all adult patients with NHL [i.e. all mature B-, T-, and natural killer (NK) cell neoplasms, with the exception of plasma cell neoplasms], newly diagnosed in the period 1989-2007 and recorded in the Netherlands Cancer Registry (n=55 069). Regular mortality data were derived from Statistics Netherlands. Follow-up was completed up to 1 January 2009. Annual percentages of change in incidence, mortality, and relative survival were calculated.
  
  
  RESULTS
  The incidence of indolent B-cell and T- and NK-cell neoplasms rose significantly (estimated annual percentage change=1.2% and 1.3%, respectively); incidence of aggressive B-cell neoplasms remained stable. Mortality due to NHL remained stable between 1989 and 2003, and has decreased since 2003. Five-year relative survival rates rose from 67% to 75%, and from 43% to 52%, respectively, for indolent and aggressive mature B-cell neoplasms, but 5-year survival remained stable at 48% for T- and NK-cell neoplasms.
  
  
  CONCLUSIONS
  In the Netherlands, incidence of indolent mature B-cell and mature T- and NK-cell neoplasms has increased since 1989 but remained stable for aggressive neoplasms. Survival increased for all mature B-cell neoplasms, preceding a declining mortality and increased prevalence of NHL (17 597 on 1 January 2008).
authors.affiliation: Eindhoven Cancer Registry, Comprehensive Cancer Centre South, Eindhoven.
authors.forename: S A M
authors.initials: SAM
authors.lastname: van de Schans
authors.affiliation: Department of Hematology, VU University Medical Center, Amsterdam.
authors.forename: D E
authors.initials: DE
authors.lastname: Issa
authors.affiliation: Comprehensive Cancer Centre Amsterdam, Amsterdam.
authors.forename: O
authors.initials: O
authors.lastname: Visser
authors.affiliation: Department of Pathology, Jeroen Bosch Hospital, 's Hertogenbosch.
authors.forename: P
authors.initials: P
authors.lastname: Nooijen
authors.affiliation: Department of Hematology, VU University Medical Center, Amsterdam.
authors.forename: P C
authors.initials: PC
authors.lastname: Huijgens
authors.affiliation: Department of Public Health, Erasmus University Medical Centre Rotterdam, Rotterdam, the Netherlands.
authors.forename: H E
authors.initials: HE
authors.lastname: Karim-Kos
authors.affiliation: Eindhoven Cancer Registry, Comprehensive Cancer Centre South, Eindhoven; Department of Public Health, Erasmus University Medical Centre Rotterdam, Rotterdam, the Netherlands.
authors.forename: M L G
authors.initials: MLG
authors.lastname: Janssen-Heijnen
authors.affiliation: Eindhoven Cancer Registry, Comprehensive Cancer Centre South, Eindhoven; Department of Public Health, Erasmus University Medical Centre Rotterdam, Rotterdam, the Netherlands. Electronic address: j.coebergh@erasmusmc.nl.
authors.forename: J W W
authors.initials: JWW
authors.lastname: Coebergh
mesh_terms: D017677:Age Distribution; D000368:Aged; D005260:Female; D006801:Humans; D015994:Incidence; D008228:Lymphoma, Non-Hodgkin / Q000453:epidemiology* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009426:Netherlands / Q000453:epidemiology; D015995:Prevalence; D012042:Registries; D015996:Survival Rate